Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Abstract Macitentan is an oral endothelin receptor antagonist for the management of pulmonary arterial hypertension (PAH). The OPsumit® USers Registry (OPUS) and the OPsumit® Historical USers cohort (OrPHeUS) medical chart review provide real‐world data for patients newly initiating macitentan. This...

Full description

Bibliographic Details
Main Authors: Vallerie V. McLaughlin, Richard Channick, Nick H. Kim, Robert P. Frantz, John W. McConnell, Lana Melendres‐Groves, Chad Miller, Ashwin Ravichandran, Josanna Rodriguez‐Lopez, Monika Brand, Sandrine Leroy, Graham Wetherill, Kelly M. Chin
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Pulmonary Circulation
Subjects:
cardiopulmonary disease
epidemiology
hepatic safety
pulmonary arterial hypertension
real‐world evidence
Online Access:https://doi.org/10.1002/pul2.12150

Internet

https://doi.org/10.1002/pul2.12150

Similar Items